S&P 500   3,382.91 (+0.08%)
DOW   27,938.98 (-0.14%)
QQQ   274.17 (+0.85%)
AAPL   461.35 (+2.06%)
MSFT   210.64 (+0.69%)
FB   263.17 (+1.26%)
GOOGL   1,524.50 (+1.15%)
AMZN   3,201.53 (+1.24%)
NVDA   462.45 (+1.06%)
CGC   17.32 (+0.41%)
BABA   254.35 (-0.33%)
TSLA   1,645.27 (+5.82%)
GE   6.62 (-1.49%)
MU   46.79 (-3.49%)
AMD   82.60 (-0.01%)
T   29.89 (-0.96%)
F   7.06 (-0.70%)
ACB   10.03 (+2.35%)
GILD   68.04 (-1.16%)
NFLX   484.10 (+1.82%)
DIS   131.65 (-0.11%)
BAC   26.25 (-1.80%)
BA   175.50 (+0.03%)
S&P 500   3,382.91 (+0.08%)
DOW   27,938.98 (-0.14%)
QQQ   274.17 (+0.85%)
AAPL   461.35 (+2.06%)
MSFT   210.64 (+0.69%)
FB   263.17 (+1.26%)
GOOGL   1,524.50 (+1.15%)
AMZN   3,201.53 (+1.24%)
NVDA   462.45 (+1.06%)
CGC   17.32 (+0.41%)
BABA   254.35 (-0.33%)
TSLA   1,645.27 (+5.82%)
GE   6.62 (-1.49%)
MU   46.79 (-3.49%)
AMD   82.60 (-0.01%)
T   29.89 (-0.96%)
F   7.06 (-0.70%)
ACB   10.03 (+2.35%)
GILD   68.04 (-1.16%)
NFLX   484.10 (+1.82%)
DIS   131.65 (-0.11%)
BAC   26.25 (-1.80%)
BA   175.50 (+0.03%)
S&P 500   3,382.91 (+0.08%)
DOW   27,938.98 (-0.14%)
QQQ   274.17 (+0.85%)
AAPL   461.35 (+2.06%)
MSFT   210.64 (+0.69%)
FB   263.17 (+1.26%)
GOOGL   1,524.50 (+1.15%)
AMZN   3,201.53 (+1.24%)
NVDA   462.45 (+1.06%)
CGC   17.32 (+0.41%)
BABA   254.35 (-0.33%)
TSLA   1,645.27 (+5.82%)
GE   6.62 (-1.49%)
MU   46.79 (-3.49%)
AMD   82.60 (-0.01%)
T   29.89 (-0.96%)
F   7.06 (-0.70%)
ACB   10.03 (+2.35%)
GILD   68.04 (-1.16%)
NFLX   484.10 (+1.82%)
DIS   131.65 (-0.11%)
BAC   26.25 (-1.80%)
BA   175.50 (+0.03%)
S&P 500   3,382.91 (+0.08%)
DOW   27,938.98 (-0.14%)
QQQ   274.17 (+0.85%)
AAPL   461.35 (+2.06%)
MSFT   210.64 (+0.69%)
FB   263.17 (+1.26%)
GOOGL   1,524.50 (+1.15%)
AMZN   3,201.53 (+1.24%)
NVDA   462.45 (+1.06%)
CGC   17.32 (+0.41%)
BABA   254.35 (-0.33%)
TSLA   1,645.27 (+5.82%)
GE   6.62 (-1.49%)
MU   46.79 (-3.49%)
AMD   82.60 (-0.01%)
T   29.89 (-0.96%)
F   7.06 (-0.70%)
ACB   10.03 (+2.35%)
GILD   68.04 (-1.16%)
NFLX   484.10 (+1.82%)
DIS   131.65 (-0.11%)
BAC   26.25 (-1.80%)
BA   175.50 (+0.03%)
Log in

NYSE:GSKGlaxoSmithKline Stock Price, Forecast & News

$41.23
-0.93 (-2.21 %)
(As of 08/13/2020 01:16 PM ET)
Add
Compare
Today's Range
$41.11
Now: $41.23
$41.56
50-Day Range
$39.91
MA: $40.88
$41.95
52-Week Range
$31.43
Now: $41.23
$48.25
Volume140,525 shs
Average Volume3.97 million shs
Market Capitalization$103.43 billion
P/E Ratio12.23
Dividend Yield4.53%
Beta0.68
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Otrivin, Panadol, Fenistil, Lamisil, Breathe Right, Stiefel, Excedrin, Physiogel, Polident, parodontax, Poligrip, Sensodyne, Theraflu, and Voltaren brand names. The company offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, syrups, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and topical creams and non-medicated patches, as well as toothpastes, toothbrushes, mouth rinses, medicated mouthwashes, gels and sprays, denture adhesives, and denture cleansers. It has a discovery collaboration agreement with Kymera Therapeutics LLC; a collaboration agreement with InSysBio LLC to develop quantitative systems pharmacology model of asthma; a strategic collaboration with NeuroMetrix, Inc. to develop and market Quell technology; and strategic alliance with Merck KGaA to jointly develop and commercialize M7824 (bintrafusp alfa), an investigational bifunctional fusion protein immunotherapy. GlaxoSmithKline plc also has a joint research collaboration with Fimbrion Therapeutics Inc. to develop a small molecule candidate for the treatment and prevention of urinary tract infections. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Read More
GlaxoSmithKline logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 3.3Insider Behavior: 3.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.04 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone44-20-8047-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$43.10 billion
Cash Flow$4.38 per share
Book Value$9.40 per share

Profitability

Net Income$5.93 billion

Miscellaneous

Employees99,437
Outstanding Shares2,508,522,000
Market Cap$103.43 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$41.23
-0.93 (-2.21 %)
(As of 08/13/2020 01:16 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GSK News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











GlaxoSmithKline (NYSE:GSK) Frequently Asked Questions

How has GlaxoSmithKline's stock been impacted by Coronavirus?

GlaxoSmithKline's stock was trading at $39.87 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GSK shares have increased by 3.4% and is now trading at $41.23.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of GlaxoSmithKline?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last year. There are currently 2 sell ratings, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for GlaxoSmithKline
.

When is GlaxoSmithKline's next earnings date?

GlaxoSmithKline is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for GlaxoSmithKline
.

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline plc (NYSE:GSK) posted its earnings results on Wednesday, July, 29th. The pharmaceutical company reported $0.48 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.49 by $0.01. The pharmaceutical company earned $9.46 billion during the quarter, compared to the consensus estimate of $9.60 billion. GlaxoSmithKline had a return on equity of 31.21% and a net margin of 19.03%.
View GlaxoSmithKline's earnings history
.

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline announced a quarterly dividend on Thursday, July 30th. Stockholders of record on Friday, August 14th will be paid a dividend of $0.4914 per share on Thursday, October 8th. This represents a $1.97 annualized dividend and a dividend yield of 4.77%. The ex-dividend date is Thursday, August 13th. This is a positive change from GlaxoSmithKline's previous quarterly dividend of $0.47.
View GlaxoSmithKline's dividend history
.

What guidance has GlaxoSmithKline issued on next quarter's earnings?

GlaxoSmithKline issued an update on its FY 2020 Pre-Market earnings guidance on Wednesday, July, 29th. The company provided earnings per share (EPS) guidance of 1.56-1.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.99.

Has GlaxoSmithKline been receiving favorable news coverage?

Media headlines about GSK stock have trended extremely negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. GlaxoSmithKline earned a news sentiment score of -4.1 on InfoTrie's scale. They also gave media coverage about the pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near term.
View the latest news about GlaxoSmithKline
.

Are investors shorting GlaxoSmithKline?

GlaxoSmithKline saw a drop in short interest in the month of May. As of May 29th, there was short interest totaling 8,650,000 shares, a drop of 22.8% from the May 14th total of 11,200,000 shares. Based on an average daily trading volume, of 4,600,000 shares, the short-interest ratio is currently 1.9 days.
View GlaxoSmithKline's Short Interest
.

Who are some of GlaxoSmithKline's key competitors?

What other stocks do shareholders of GlaxoSmithKline own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GlaxoSmithKline investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Gilead Sciences (GILD), Intel (INTC), Walt Disney (DIS) and NVIDIA (NVDA).

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the following people:
  • Ms. Emma N. Walmsley, CEO & Director (Age 49)
  • Mr. Simon P. Dingemans, CFO & Exec. Director (Age 55)
  • Dr. Hal V. Barron, Chief Scientific Officer, Pres of R&D and Director (Age 56)
  • Mr. Jack Bailey, Pres of US Pharmaceuticals
  • Ms. Karenann K. Terrell, Chief Digital & Technology Officer (Age 57)

What is GlaxoSmithKline's stock symbol?

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

Who are GlaxoSmithKline's major shareholders?

GlaxoSmithKline's stock is owned by a number of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.63%), Black Creek Investment Management Inc. (0.23%), Rockefeller Capital Management L.P. (0.11%), Goldman Sachs Group Inc. (0.11%), Macquarie Group Ltd. (0.08%) and Bank of New York Mellon Corp (0.06%).
View institutional ownership trends for GlaxoSmithKline
.

Which institutional investors are selling GlaxoSmithKline stock?

GSK stock was sold by a variety of institutional investors in the last quarter, including Rockefeller Capital Management L.P., Goldman Sachs Group Inc., Twin Tree Management LP, Black Creek Investment Management Inc., Grantham Mayo Van Otterloo & Co. LLC, Brandes Investment Partners LP, Bank of New York Mellon Corp, and Envestnet Asset Management Inc..
View insider buying and selling activity for GlaxoSmithKline
.

Which institutional investors are buying GlaxoSmithKline stock?

GSK stock was purchased by a variety of institutional investors in the last quarter, including Thrivent Financial for Lutherans, Fisher Asset Management LLC, CWM LLC, LSV Asset Management, Douglas Lane & Associates LLC, HighTower Advisors LLC, Polaris Greystone Financial Group LLC, and Pacer Advisors Inc..
View insider buying and selling activity for GlaxoSmithKline
.

How do I buy shares of GlaxoSmithKline?

Shares of GSK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is GlaxoSmithKline's stock price today?

One share of GSK stock can currently be purchased for approximately $41.23.

How big of a company is GlaxoSmithKline?

GlaxoSmithKline has a market capitalization of $103.43 billion and generates $43.10 billion in revenue each year. The pharmaceutical company earns $5.93 billion in net income (profit) each year or $3.17 on an earnings per share basis. GlaxoSmithKline employs 99,437 workers across the globe.

What is GlaxoSmithKline's official website?

The official website for GlaxoSmithKline is www.gsk.com.

How can I contact GlaxoSmithKline?

GlaxoSmithKline's mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The pharmaceutical company can be reached via phone at 44-20-8047-5000 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.